InícioHealth and EnvironmentThe new england journal of medicine Stopcovid Tofacitinib in Patients Hospitalized...

The new england journal of medicine Stopcovid Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

sábado, abril 20, 2024

Original Article /ABSTRACT

Posted by by

Dra Janice Caron Nazareth

The New England Journal of Medicine

Stopcovid 

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Patrícia O. Guimarães, M.D., Ph.D., Daniel Quirk, M.D., M.P.H.,
Remo H. Furtado, M.D., Ph.D., Lilia N. Maia, M.D., Ph.D., José F. Saraiva, M.D., Ph.D., Murillo O. Antunes, M.D., Ph.D., Roberto Kalil Filho, M.D., Ph.D.,
Vagner M. Junior, M.D., Alexandre M. Soeiro, M.D., Alexandre P. Tognon, M.D., Ph.D., Viviane C. Veiga, M.D., Ph.D., Priscilla A. Martins, M.D., Diogo D.F. Moia, Pharm.D., Bruna S. Sampaio, B.Sc., Silvia R.L. Assis, M.S., Ronaldo V.P. Soares, Pharm.D., Luciana P.A. Piano, Ph.D., Kleber Castilho, M.B.A., Roberta G.R.A.P. Momesso, Ph.D., Frederico Monfardini, M.Sc., Helio P. Guimarães, M.D., Ph.D.,
Dario Ponce de Leon, M.D., Majori Dulcine, M.D., Marcia R.T. Pinheiro, M.D., Levent M. Gunay, M.D., J. Jasper Deuring, Ph.D., Luiz V. Rizzo, M.D., Ph.D., Tamas Koncz, M.D., Ph.D., and Otavio Berwanger, M.D., Ph.D.,
for the STOP-COVID Trial Investigators*

BACKGROUND

The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear.

METHODS

We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumo- nia to receive either tofacitinib at a dose of 10 mg or placebo twice daily for up to 14 days or until hospital discharge. The primary outcome was the occurrence of death or respiratory failure through day 28 as assessed with the use of an eight- level ordinal scale (with scores ranging from 1 to 8 and higher scores indicating a worse condition). All-cause mortality and safety were also assessed.

RESULTS

A total of 289 patients underwent randomization at 15 sites in Brazil. Overall, 89.3% of the patients received glucocorticoids during hospitalization. The cumula- tive incidence of death or respiratory failure through day 28 was 18.1% in the to- facitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% confidence interval [CI], 0.41 to 0.97; P=0.04). Death from any cause through day 28 occurred in 2.8% of the patients in the tofacitinib group and in 5.5% of those in the pla- cebo group (hazard ratio, 0.49; 95% CI, 0.15 to 1.63). The proportional odds of having a worse score on the eight-level ordinal scale with tofacitinib, as compared with placebo, was 0.60 (95% CI, 0.36 to 1.00) at day 14 and 0.54 (95% CI, 0.27 to 1.06) at day 28. Serious adverse events occurred in 20 patients (14.1%) in the to- facitinib group and in 17 (12.0%) in the placebo group.

CONCLUSIONS

Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. (Funded by Pfizer; STOP-COVID ClinicalTrials.gov number, NCT04469114.)

The authors’ affiliations are listed in the Appendix. Address reprint requests to Dr. Berwanger at the Hospital Israelita Albert Einstein, Av. Albert Einstein 627, São Paulo 05620-900, Brazil, or at [email protected].

*A list of the STOP-COVID Trial Investi- gators is provided in the Supplemen- tary Appendix, available at NEJM.org.

This article was published on June 16, 2021, at NEJM.org.

DOI: 10.1056/NEJMoa2101643

Copyright © 2021 Massachusetts Medical Society.

 

Artigos Mais Recentes

Libertarismo na América Latina: O Novo Momento Político Inspirado por Javier Milei – Libertarianism in Latin America: The New Political Moment...

Comente, curta e compartilhe -  Remember to comment, like and shareO cenário político da...

Bastidores Revelados: O Jogo de Guerra do Irã para Acalmar seus Radicais – Behind the Scenes Revealed: Iran’s War...

Comente, curta e compartilhe - Remember to comment, like and shareOs acontecimentos recentes entre...

Uma Visão Multimodal para o Futuro: Transformando a Mobilidade em Florianópolis: – A Multimodal Vision for the Future

Lembre-se de comentar, curtir e compartilhar Remember to comment, like and shareEm meio aos...

Rua  Avanhandava: a História de Walter Mancini e seu Legado de Generosidade – Avanhandava Street: The Story of Walter Mancini and His Legacy...

Lembre-se de comentar, curtir e compartilhar Remember to comment, like and share Num cenário onde...

DEIXE UMA RESPOSTA

Por favor digite seu comentário!
Por favor, digite seu nome aqui


Mais como isso

Vinho Tinto: Entre os Brindes à Saúde e os Alertas para o Coração – Red Wine: Between Health Benefits and Heart Alerts

O vinho tinto tem sido objeto de interesse científico há décadas, com estudos apontando...

Conexões Científicas em Tempos de Pandemia: o Legado Transformador do Covid-19 / Scientific Connections in Times of Pandemic: the Transformative Legacy of Covid-19

LEIA, COMENTE, COMPARTILHE  E  SINALIZE SUA OPINIÃO... A pandemia de Covid-19 não apenas desencadeou crises...

Novidades